CYT006-AngQb

Summary

CYT006-AngQb is an anti-angiotensin II therapeutic vaccine developed by Cytos Biotechnology for the treatment of arterial hypertension. By generating endogenous antibodies against angiotensin II, it aims to provide long-lasting blood pressure control with infrequent dosing (a few injections per year). Phase IIa clinical trials demonstrated significant reductions in ambulatory blood pressure, particularly in morning blood pressure surges, but further development was discontinued.

Mechanism of Action

CYT006-AngQb is a therapeutic vaccine consisting of angiotensin II peptides conjugated to Qβ bacteriophage virus-like particles. It stimulates the immune system to generate polyclonal antibodies against angiotensin II, thereby reducing circulating angiotensin II levels and attenuating its vasoconstrictive and aldosterone-stimulating effects, leading to sustained blood pressure reduction.

Routes of Administration

Goals & Uses

• Morning blood pressure surge attenuationCardiovascularModerate
• Long-term antihypertensive control with infrequent dosingCardiovascular / AdherenceLow
• Blood pressure reduction in arterial hypertensionCardiovascularModerate

Contraindications

• Autoimmune diseaseImmuneModerateMay worsen or interact with immune-mediated disease
• Severe renal artery stenosisRenal/VascularHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Known hypersensitivity to vaccine components or bacteriophage proteinsImmunologicalHigh

Adverse Effects

• Flu-like symptomsSystemic/ImmunologicalCommon
• Injection site reactionsLocalCommon
• HypotensionCardiovascularUncommonLow blood pressure
• Renal function impairmentRenalRare

Drug Interactions

• Angiotensin Receptor Blockers (ARBs)Moderate
• ACE inhibitorsModerate
• ImmunosuppressantsModeratePotential interaction with immune pathways or infection risk
• Potassium-sparing diureticsModerate

Population Constraints

• Pediatric patientsAgeAbsolute
• Immunocompromised patientsImmunologicRelative
• Pregnant womenReproductiveAbsolute
• Patients with severely compromised renal functionRenalRelative

Regulatory Status

• European UnionInvestigationalPhase IIa trials conducted in Europe (Switzerland); no marketing authorization pursued.
• United StatesInvestigationalNever filed for approval; development discontinued after Phase IIa.
• United KingdomUnknownNo specific regulatory filing or approval record in the UK.

CYT006-AngQb was evaluated in Phase IIa clinical trials but did not progress to Phase III. No regulatory approval has been granted in any jurisdiction. Development was discontinued by Cytos Biotechnology.

Evidence & Sources

No sources recorded yet.